Cassava Sciences | PTIE - Current Liabilities


Cassava Sciences reported $40.11M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Amgen USD 25.5B 547M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
Cassava Sciences USD 40.11M 3.72M Mar/2026
Eisai JPY 393.64B 53.39B Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Geron USD 73.57M 40.25M Mar/2026
J&J USD 54.9B 2.82B Jun/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026